Abstract
Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Volume: 9 Issue: 2
Author(s): Tianfu Wu and Chandra Mohan
Affiliation:
Abstract: Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Export Options
About this article
Cite this article as:
Wu Tianfu and Mohan Chandra, The AKT Axis as a Therapeutic Target in Autoimmune Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187153009788452417
DOI https://dx.doi.org/10.2174/187153009788452417 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atherosclerosis, Degenerative Aortic Stenosis and Statins
Current Drug Targets Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Putting Evidence for Diabetes Care into Practice
Current Diabetes Reviews Hypertension and Diabetes: Emphasis on the Renin – Angiotensin System and Insulin Resistance
Current Hypertension Reviews An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry <i>Ononis natrix</i> L. Lowers the Blood Glucose Concentration in Wistar Rats with Streptozotocin-induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics
Current Pharmaceutical Design Natural Approaches in Diabetes Management: A Review of Diet, Exercise, and Natural Products
Current Pharmaceutical Design Painful Peripheral Neuropathies
Current Neuropharmacology Epigenetic Changes in the Methylation Patterns of KCNQ1 and WT1 after a Weight Loss Intervention Program in Obese Stroke Patients
Current Neurovascular Research Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy
Current Radiopharmaceuticals New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Current Pharmaceutical Design Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial:
Current Diabetes Reviews